JP2015535274A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535274A5
JP2015535274A5 JP2015540222A JP2015540222A JP2015535274A5 JP 2015535274 A5 JP2015535274 A5 JP 2015535274A5 JP 2015540222 A JP2015540222 A JP 2015540222A JP 2015540222 A JP2015540222 A JP 2015540222A JP 2015535274 A5 JP2015535274 A5 JP 2015535274A5
Authority
JP
Japan
Prior art keywords
acid
tapentadol
ester
base
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535274A (ja
JP6360488B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/056082 external-priority patent/WO2014068372A1/en
Publication of JP2015535274A publication Critical patent/JP2015535274A/ja
Publication of JP2015535274A5 publication Critical patent/JP2015535274A5/ja
Application granted granted Critical
Publication of JP6360488B2 publication Critical patent/JP6360488B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540222A 2012-11-01 2012-11-01 非経口投与のためのタペンタドールの薬学的組成物 Expired - Fee Related JP6360488B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/056082 WO2014068372A1 (en) 2012-11-01 2012-11-01 Pharmaceutical composition of tapentadol for parenteral administration

Publications (3)

Publication Number Publication Date
JP2015535274A JP2015535274A (ja) 2015-12-10
JP2015535274A5 true JP2015535274A5 (enExample) 2018-06-14
JP6360488B2 JP6360488B2 (ja) 2018-07-18

Family

ID=47297340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540222A Expired - Fee Related JP6360488B2 (ja) 2012-11-01 2012-11-01 非経口投与のためのタペンタドールの薬学的組成物

Country Status (7)

Country Link
US (1) US9629818B2 (enExample)
EP (1) EP2914243A1 (enExample)
JP (1) JP6360488B2 (enExample)
KR (1) KR20150075408A (enExample)
BR (1) BR112015009839A2 (enExample)
CA (1) CA2890270A1 (enExample)
WO (1) WO2014068372A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20170290771A1 (en) * 2016-04-12 2017-10-12 Southern Research Institute Biodegradable in situ forming microparticles and methods for producing the same
ES3027562T3 (en) * 2016-09-23 2025-06-16 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
EP3793536A1 (en) 2018-05-12 2021-03-24 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
KR101851120B1 (ko) * 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
WO2010124856A1 (en) * 2009-04-30 2010-11-04 Grünenthal GmbH Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
AR077225A1 (es) * 2009-06-24 2011-08-10 Organon Nv Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
US8288592B2 (en) * 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
AU2011222644A1 (en) * 2010-03-05 2012-09-06 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
WO2011139595A2 (en) * 2010-04-27 2011-11-10 Medtronic, Inc. Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
MX341072B (es) 2010-07-23 2016-08-05 Grünenthal Gmbh * Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
DK2680833T3 (en) 2011-03-04 2016-05-23 Gruenenthal Gmbh PARENTERAL SUBMISSION OF TAPENTADOL

Similar Documents

Publication Publication Date Title
JP2015535274A5 (enExample)
JP5728128B2 (ja) リスペリドン徐放性ミクロスフェア組成物
US20240189223A1 (en) Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
US20140243278A1 (en) Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
JP6249944B2 (ja) 注射製剤
CN1917859A (zh) 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂
JP6360488B2 (ja) 非経口投与のためのタペンタドールの薬学的組成物
WO2010118639A1 (zh) 氨氯地平微球制剂、其制备方法及应用
JP4551988B2 (ja) 2−メチル−チエノ−ベンゾジアゼピン製剤
WO2006032202A1 (fr) Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
JP2014501781A5 (enExample)
KR20190005183A (ko) 풀베스트란트 제제 및 그의 사용 방법
Panda et al. Ibuprofen loaded electrospun polymeric nanofibers: A strategy to improve oral absorption
Bhowmik et al. Solid dispersion-a approach to enhance the dissolution rate of poorly water soluble drugs
WO2012026896A1 (en) Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
JP6120876B2 (ja) Hiv吸着阻害剤のプロドラッグ化合物と賦形剤の共処理方法および製剤
AU2018354431A1 (en) Dosage regimen of paliperidone palmitate extended-release injectable suspension
JP2009545564A (ja) 長時間にわたって活性本体を放出する皮下移植物
CN106265524A (zh) 盐酸沙拉沙星固体分散制剂及其制备方法
TW202216150A (zh) 包含p2y12受體拮抗劑的水性醫藥組合物
CA2871886A1 (en) Amorphous dispersions of paroxetine mesylate
Lan et al. Poloxamers as Solubilizing Agents in Solid Dispersions
WO2011148253A2 (en) Solid dosage forms of antipsychotics
JPWO2000078318A1 (ja) 経口用医薬組成物